J. Goldman & CO LP Provention Bio, Inc. Transaction History

J. Goldman & CO LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$10.12 - $19.45 $295,615 - $568,153	-29,211 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$11.79 - $18.94 $160,108 - $257,205	-13,580 Reduced 31.74%	29,211 $495,000
Q3 2020 Nov 16, 2020	SELL	$10.34 - $15.2 $225,443 - $331,405	-21,803 Reduced 33.75%	42,791 $549,000
Q2 2020 Aug 14, 2020	BUY	$7.81 - $17.0 $348,286 - $758,115	44,595 Added 222.99%	64,594 $911,000
Q1 2020 May 15, 2020	SELL	$5.42 - $17.75 $128,242 - $419,982	-23,661 Reduced 54.19%	19,999 $184,000
Q4 2019 Feb 14, 2020	BUY	$5.84 - $14.9 $254,974 - $650,534	43,660 New	43,660 $651,000

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.